Agios Pharmaceuticals (AGIO) Cost of Revenue (2018 - 2025)
Historic Cost of Revenue for Agios Pharmaceuticals (AGIO) over the last 7 years, with Q4 2025 value amounting to $1.9 million.
- Agios Pharmaceuticals' Cost of Revenue rose 4912.7% to $1.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $6.3 million, marking a year-over-year increase of 5234.09%. This contributed to the annual value of $6.3 million for FY2025, which is 5234.09% up from last year.
- Agios Pharmaceuticals' Cost of Revenue amounted to $1.9 million in Q4 2025, which was up 4912.7% from $1.7 million recorded in Q3 2025.
- In the past 5 years, Agios Pharmaceuticals' Cost of Revenue registered a high of $1.9 million during Q4 2025, and its lowest value of $339000.0 during Q1 2022.
- Over the past 4 years, Agios Pharmaceuticals' median Cost of Revenue value was $708000.0 (recorded in 2023), while the average stood at $943437.5.
- Per our database at Business Quant, Agios Pharmaceuticals' Cost of Revenue skyrocketed by 15471.26% in 2023 and then skyrocketed by 1317.69% in 2024.
- Over the past 4 years, Agios Pharmaceuticals' Cost of Revenue (Quarter) stood at $413000.0 in 2022, then skyrocketed by 41.89% to $586000.0 in 2023, then skyrocketed by 115.02% to $1.3 million in 2024, then skyrocketed by 49.13% to $1.9 million in 2025.
- Its Cost of Revenue was $1.9 million in Q4 2025, compared to $1.7 million in Q3 2025 and $1.7 million in Q2 2025.